DIGITAL HEALTHCARE

Resilient Healthcare Partners with Medical City Healthcare to Bring High-Acuity Care to the Home

Resilient Healthcare | November 15, 2021

As COVID-19 continues across North Texas, Resilient Healthcare, a leader in the at-home acute care space, has partnered with Medical City Healthcare, one of the most comprehensive healthcare providers in North Texas, to deliver high-acuity care in the home.

The partnership is significant as Medical City Healthcare is the first network of hospitals in Texas to receive approval from the Centers of Medicare and Medicaid Services (CMS) to participate in the Acute Hospital at Home Program, which allows qualifying patients with certain conditions to receive high-acuity care in their homes. At-home care is supported by 24/7 remote monitoring, daily provider visits and other necessary support. Resilient Healthcare will deliver at-home care on behalf of Medical City Healthcare hospitals in North Texas. Patients can only be admitted to the program from emergency departments or inpatient hospital beds and admission requires an in-person physician evaluation prior to starting services at home.

"As we have done throughout the pandemic, Medical City Healthcare's preparedness response has been to balance our readiness to care for COVID-19 patients while continuing to make sure the many other patients who depend on our hospitals receive needed and timely care," says Medical City Healthcare Chief Medical Officer Joseph Parra, MD. "The partnership with Resilient allows us to continue to provide excellent and compassionate care outside the hospital walls for patients who qualify."

Hospital-Grade Care in the Home at a Glance

Once at home, qualifying patients will receive all the necessary diagnostic and medical treatments they would receive during a typical hospital stay including imaging, labs, IV and oral medications, home nursing and therapy, virtual doctor visits and continuous telemetry and monitoring.

"Our patient-centered model opens up inpatient beds to allow for higher-acuity care while providing high-quality care in the comfort of the patient's home. That is a benefit for patients, families, hospitals and insurers."

Resilient's Vice President of Operations Brian Chace, PT, DPT

About Resilient Healthcare
Resilient Healthcare has become the leader in the at-home acute care space. Its LTAC@H™ Program is the first of its kind, in which seriously ill patients have access to an array of hospital-grade healthcare services from the comfort of their homes, both virtually and in-person. Resilient Healthcare began as a vision for a better healthcare delivery system in 2018. Its technology subsidiary, Artic was established in 2020 with the overarching goal of developing software to convert homes into clinical spaces, coordinate care efficiently and optimize health risk stratification.

About Medical City Healthcare
Committed to the care and improvement of human life, Medical City Healthcare strives to deliver excellence always, providing high-quality healthcare in the communities it serves. With the resources and strength of HCA Healthcare, the nation's leading provider of quality healthcare services with 185 hospitals in the United States and England, Medical City Healthcare is one of the North Texas region's largest and most comprehensive healthcare providers. It includes 16 hospitals with 3,662 licensed beds, nearly 5,000 active physicians, 6,000 nurses, 17,000 employees, 11 ambulatory surgery centers, 4 off-campus emergency rooms and CareNow Urgent Care clinics. Three Medical City Healthcare hospitals are accredited comprehensive stroke centers, 10 hospitals "A" safety rated by the Leapfrog Group and eight hospitals hold the prestigious Magnet Recognized® status from the American Nurses Credentialing Center.

Spotlight

Building a new center of ten operational theatres, the Ortenau Klinikum in Lahr Ettenheim relied on a total solution from Dräger. Providing major planning support during the implementation as well as one key contact, Dräger also offered a homogeneous fleet including ceiling supply units, lamps and monitors that allow ergonomic processes and reduce the workload for designers and builders. The medical planner Hans-Georg Averdunk from the Hospitaltechnik Planungsgesellschaft sees many benefits: The advantage of the overall concept is that all the elements of the operating theatre environment are perfectly aligned with one another.


Other News
MEDICAL DEVICES

Astorg Acquires Majority Interest in Avania

Avania | June 21, 2022

Avania, the preeminent, full-service global MedTech contract research organization announced that Astorg has acquired a majority stake in the company. Astorg, together with Kester Capital current investor who intends to retain a minority stake will actively support management’s plans to advance Avania’s development as a MedTech solution provider. Headquartered in the Netherlands, Avania was formed in March 2020 from the combination of five complementary businesses and started a successful journey to establish a fully integrated platform to serve sponsors worldwide in advancing medical technology products from early development to post-market ensuring customized, scalable solutions that optimize efficiencies and streamline the advancement of medical technology. Astorg brings an impressive global network of relationships in the MedTech space which will strengthen Avania’s pipeline and broaden its customer base while the capital access will help accelerate its growth, both organically and via acquisitions. “The platform we have built has positioned us ahead of our competition in the MedTech CRO space, and this deal will bring additional investment to strengthen our infrastructure, capital for acquisitions, and added support as we continue to grow Avania into the clear market leader. The largest CROs do not have the specialization that we bring, and the regional niche providers do not have the scale and reach of Avania. This unique positioning, along with the continued changes to the MedTech regulatory landscape, will allow us to push ourselves to the next era of growth.” Sapna Hornyak, president and CEO of Avania “We are extremely pleased to partner with Sapna and her team, as well as Kester, on this transaction,” said Managing Partner of Astorg Mid-Cap Edouard Pillot. “Being one of the global leaders in a profitable and fast-growing niche market, Avania squarely fits with Astorg’s investment criteria, and we are delighted to have Avania as our first Mid-Cap Healthcare deal, sitting within Astorg’s broader healthcare portfolio.” About Avania Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical technology, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being. About Astorg Astorg is a leading private equity firm with over €17 billion of assets under management. We work with entrepreneurs and management teams to acquire market-leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance, and capital they need to achieve their growth goals. Astorg enjoys a distinct entrepreneurial culture, a long-term shareholder perspective, and a lean decision-making body. We have valuable industry expertise in healthcare, software, business-to-business professional services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan and Luxembourg. About Kester Capital Kester Capital is a primary buy-out specialist. Kester focuses on the healthcare, data & information and technology sectors, targeting businesses that require capital in order to unlock their potential.

Read More

HEALTH TECHNOLOGY

Ivenix to be Acquired by Fresenius Kabi

Ivenix | April 01, 2022

Ivenix, Inc. announced that it has entered into a definitive agreement to be acquired by Fresenius Kabi, a global health care leader specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Ivenix’s advanced infusion system combined with Fresenius Kabi’s intravenous fluids and infusion therapy offerings will bring a comprehensive portfolio of infusion products to U.S. hospitals. The purchase price will be a combination of US$240 million upfront payment and milestone payments linked to achievements of commercial and operating targets. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close by mid-2022. The transaction is designed to Create a comprehensive portfolio that joins the industry’s most advanced infusion pump technology with the newest source of intravenous fluids, infusion supplies and accessories. Accelerate operational and commercial growth and scale providing a platform for rapid expansion. Build on a shared culture of exceptional customer service. Establish Fresenius Kabi as a leader in the approximately $5 billion infusion segment. This pivotal transaction will accelerate innovation, expand our combined infusion therapy portfolio and enhance our infusion capabilities, resulting in improved medication safety and operational efficiency. “We’re very pleased to partner with Fresenius Kabi, a leading global health care company. Together, we intend to transform the standard of care for North American health care providers and patients by providing the highest level of safe and effective integrated infusion care,” Jorgen B. Hansen, Ivenix’s Chief Executive Officer The Ivenix Infusion System includes a large-volume infusion pump with administration sets, infusion management tools, and analytics to inform care and advance efficiency. Ivenix centered the system around the patient and clinician and designed it to reduce infusion-related errors and drive down the total cost of ownership. After receiving U.S. Food and Drug Administration (FDA) clearance, Ivenix successfully launched the infusion system in 2021. “Combining Ivenix’s expertise in pump technology and software with our infrastructure, portfolio, and presence in hospital settings represents an ideal opportunity. We intend to scale the launch of Ivenix’s next-generation infusion system while driving growth opportunities in the United States. With today’s announcement, Fresenius Kabi expects to create a leading, comprehensive infusion therapy offering,” said Michael Sen, President and CEO, Fresenius Kabi. About Ivenix Ivenix, Inc. is a medical technology company with a vision to eliminate infusion-related patient harm. The company was founded to develop innovative solutions that transform infusion delivery. Ivenix designed an infusion system from the ground up to streamline medication delivery and bring infusion technology into the digital age. The Ivenix Infusion System includes a large-volume infusion pump supported by a robust infusion management system designed to set new standards in simplicity, intelligence, and reliability. For more information, visit ivenix.com. The Ivenix Infusion System is cleared by the FDA.

Read More

FUTURE OF HEALTHCARE

Dalrada Accelerates Its National Healthcare Model With Acquisition of Watson Rx Solutions

Dalrada Corporation | June 09, 2022

Dalrada Corporation announced that it had acquired the pharmacy, Watson Rx Solutions, Inc. The move highlights Dalrada’s aggressive growth plans within the healthcare sector and paves the way for a total end-to-end total healthcare solution. Adding the 10-year-old pharmacy to Dalrada Health’s comprehensive model expands the subsidiary’s synergies with potential opportunities across its products and services portfolio and offers another solution to meet patient requirements. Dalrada envisions a comprehensive healthcare solution for all Dalrada Health clients with unique offerings that will now include: a pharmacy to facilitate prescription processing, physicians and clinicians at treatment clinics, expanding into telemedicine, engagement of Dalrada-owned testing facilities and laboratories, and utilization of Company-specific technologies to facilitate immediate growth of the business. “Watson Rx has a long history of providing excellent pharmacy services. This acquisition allows Dalrada to expand its healthcare footprint and continue to build a total health management solution on an already successful turnkey operation. As a result, the Company will be able to successfully address the health needs of even more patients.” CEO and Founder, Brian Bonar Through comprehensive prescription management, education, nursing, and total health management, Watson Rx Solutions' leadership team holds more than six decades of combined experience in various complex pharmacy disease states and retail services, always putting patients first. Dalrada plans on entering the pharmaceutical space with an accelerated strategic plan to leverage the Company’s existing capabilities. Research reveals that the U.S. online and mail-order sales of drugs, health, and beauty aids were valued at 75.5 billion USD in 2020. Additionally, E-commerce pharmaceutical sales and beauty aids increased from 51.7 billion USD the year prior. Online, E-commerce, and mail-order sales increased from around 31 to 38 percent during the same period. Pharmacy and drug store sales reached 300 billion USD in 2020, with over-the-counter (OTC) medication accounting for over 36 billion USD in sales during the same year, the highest-selling year to date for the OTC segment. Dalrada and its subsidiaries provide value by making timely and impactful products and services available within health, technology, and clean energy markets. About Dalrada Dalrada Corporation drives innovation that positively impacts people, businesses, and the planet. With subsidiaries that are firmly positioned in the world’s top three-growing industries of healthcare, clean energy, and technology, Dalrada creates solutions that are sustainable, affordable, and accessible. The company works continually to produce disruptive products and services that accelerate positive change for current and future generations. Dalrada’s global solutions directly address climate change, post-pandemic gaps in the healthcare industry, and technology solutions for a new era of human behavior and interaction, ensuring a bright future for the world around us.

Read More

FUTURE OF HEALTHCARE

OmniLife Partners With Redox to Add Patient Referral Management Tool to Its End-to-End Communication Platform for Transplant Hospitals.

OmniLife | March 25, 2022

OmniLife, a health technology communication and collaboration platform, has partnered with Redox, the industry-leading electronic health record integration and healthcare interoperability platform, to create a new integrated patient management tool as part of its overarching platform that provides end-to-end communication solutions for transplant hospitals. The new patient modules, OmniReferral and PatientStatus, will allow transplant centers to easily review new referrals and share updates on patient status to providers and allows transplant centers to customize their own digital forms to make it easier for providers to refer and then monitor the activity and status of transplant patients. The tool also integrates into the EHR patient checklists and allows centers using EHRs to easily share patient status updates with referring providers. OmniReferral and PatientStatus is built to be organ agnostic, allowing centers to use the tool across all organ departments and with any referring provider. OmniLife has been leading efforts to improve communication, decision making, and secure information exchange between all stakeholders in the greater allotransplant ecosystem. Additionally, OmniLife is currently participating in a clinical trial funded by the National Institutes of Health (NIH) for a Small Business Innovation Research (SBIR) which includes notable centers such as UPMC Children’s Hospital of Pittsburgh, Loma Linda University Transplant Institute, and Stanford Health Care Transplant Program. About OmniLife OmniLife is a certified Benefit Corporation focused on maximizing the gift of life for purposes of transplantation and research. OmniLife is the only end-to-end communication and clinical workflow software platform that is built specifically to create a more connected and collaborative allotransplant ecosystem.

Read More

Spotlight

Building a new center of ten operational theatres, the Ortenau Klinikum in Lahr Ettenheim relied on a total solution from Dräger. Providing major planning support during the implementation as well as one key contact, Dräger also offered a homogeneous fleet including ceiling supply units, lamps and monitors that allow ergonomic processes and reduce the workload for designers and builders. The medical planner Hans-Georg Averdunk from the Hospitaltechnik Planungsgesellschaft sees many benefits: The advantage of the overall concept is that all the elements of the operating theatre environment are perfectly aligned with one another.

Resources